Integrated analysis of RNA and DNA from the phase III trial CALGB 40601 identifies predictors of response to trastuzumab-based neoadjuvant chemotherapy in HER2-positive breast cancer

PURPOSE: Response to a complex trastuzumab-based regimen is affected by multiple features of the tumor and its microenvironment. Developing a predictive algorithm is key to optimizing HER2-targeting therapy. METHODS: We analyzed 137 pre-treatment tumors with mRNA-seq and DNA exome sequencing from CA...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Tanioka, Maki, Fan, Cheng, Parker, Joel S, Hoadley, Katherine A, Hu, Zhiyuan, Li, Yan, Hyslop, Terry M, Pitcher, Brandelyn N, Soloway, Matthew G, Spears, Patricia A, Henry, Lynn N, Tolaney, Sara, Dang, Chau T, Krop, Ian E, Harris, Lyndsay N, Berry, Donald A, Mardis, Elaine R, Winer, Eric P, Hudis, Clifford A, Carey, Lisa A, Perou, Charles M
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6214737/
https://ncbi.nlm.nih.gov/pubmed/30037817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3431
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados